Table 3 Concomitant methotrexate numbers, dose categories and exposure by anti-TNF agent

Agent	Receiving concomitant methotrexate	Dose			Active treatment		Control
Agent	Receiving concomitant methotrexate	Low	Recommended	High	N	Patient-years*	N	Patient-years*
Adalimumab	47%†	175 (8%)	1643 (77%)	318 (15%)	2136	0.83	1017	0.81
Etanercept	27%†	284 (15%)	1635 (85%)	0 (0%)	1919	0.91	927	0.87
Infliximab	98%†	29 (1%)	897 (45%)	1073 (54%)	1999	0.79	810	0.64
Total	57%	488 (8%)	4175 (69%)	1391 (23%)	6054	0.84	2754	0.78

*Total exposure in controlled phases of the study. †Adalimumab versus etanercept, adalimumab versus infliximab, infliximab versus etanercept, p<0.001. ‡Active versus control. TNF, tumour necrosis factor.